Dianthus Therapeutics Banner

SEC Filing Details

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Press Release

Document Details

Form
144
Filing Date
Jun 1, 2026
Document Date
Jun 1, 2026
Form Description
Filed by "insiders" prior intended sale of restricted stock.
Filing Group
Other
Company
Dianthus Therapeutics
Issuer
DIANTHUS THERAPEUTICS, INC. /DE/

Filing Formats

View HTML
Download PDF
Download DOC